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Because obesity is frequently complicated by other cardio-
vascular risk factors, the impact of a reduction in visceral
adiposity on vascular endothelial dysfunction (VED) in obese
patients is difficult to determine. In the present study, we
evaluated the impact of a reduction in visceral adiposity on
VED in obese women. Thirty-six premenopausal obese women
(BMI 25 kg/m
2) without complications were enrolled in the
study. VED was evaluated by determining the augmentation
index (AIx) from radial artery pulse waves obtained by appla-
nation tonometry. Changes in AIx in response to nitroglycerin-
induced endothelium-independent vasodilatation ( AIx-NTG)
and in response to salbutamol administration ( AIx-Salb)
were determined before and after weight reduction. After a
12-week weight reduction program, the average weight loss
was 7.96±3.47 kg, with losses of 21.88±20.39 cm
2 in vis-
ceral fat areas (p < 0.001). Pulse wave analysis combined with
provocative pharmacological testing demonstrated preserved
endothelium-independent vasodilation in healthy premenopaus-
al obese women ( AIx-NTG: 31.36±9.80% before weight re-
duction vs. 28.25 ± 11.21% after weight reduction, p > 0.1)
and an improvement in endothelial-dependent vasodilation fol-
lowing weight reduction ( AIx-Salb: 10.03±6.49% before
weight reduction vs. 19.33 ± 9.28% after reduction, p < 0.001).
A reduction in visceral adipose tissue was found to be most
significantly related to an increase in AIx-Salb (β=-0.57,
p < 0.001). A reduction in visceral adiposity was significantly
related to an improvement in VED. This finding suggests that
reduction of visceral adiposity may be as important as the
control of other major risk factors in the prevention of
atherosclerosis in obese women.
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INTRODUCTION
Obesity is an independent risk factor for cardio-
vascular disease.
1,2 In particular, abdominal vis-
ceral adipose tissue is believed to have harmful
effects on vascular endothelial function through
various interactions of coagulants and inflamma-
tory molecules.
3 The vascular endothelium serves
as an endocrine organ, secreting several vasoactive
substances, such as nitric oxide. These substances
prevent the development of atheroma. Obesity is
independently associated with vascular endothe-
lial dysfunction (VED,) and VED is a key event in
the early development of atherosclerosis. Therefore,
VED may be an important link between obesity
and atherosclerosis. Weight reduction has been re-
ported to improve VED.
4 However, because obesity
is frequently accompanied by other cardiovascu-
lar risk factors and metabolic diseases, the ability
of reduced visceral adiposity alone to improve VED
in obese patients has been difficult to determine.
A simple, non-invasive pulse wave analysis




7 a β2 -agonist, reduces wave
reflection by activating the L-arginine-NO path-
way, many studies have shown that an assess-
ment of global endothelial function can be per-
formed by examining changes in the peripheral
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waveform in response to inhalation of β2-ago-
nists. Changes can be measured by tonometry and
quantified according to the augmentation index
(AIx).
5,6 The present study utilized the advanta-
ges of pulse wave analysis, i.e., its simplicity, re-
peatability, operator-independency and non-inva-
siveness. We evaluated the impact of substantial
weight reduction on VED in premenopausal obese
women without complications or any other car-
diac risk factors to determine whether weight re-
duction alone was associated with improved VED.
MATERIALS AND METHODS
Subjects
The same healthy, premenopausal obese women
included in a previous study
8 were enrolled in the
present study. These subjects were visiting a
university hospital obesity clinic and were 20 to
45 years-old (mean age: 33.81 ± 7.13) with a body
mass index (BMI) 25 kg/m
2. Obesity was de-
fined according to the guidelines established by
the 'Redefining Obesity and its Treatment'- a Joint
Enterprise by the Regional Office for the Western
Pacific of the World Health Organization and the
International Association for the Study of Obesity
and International Obesity Task Force. Subjects
with any of the following co-morbidities were ex-
cluded: hypertension (systolic blood pressure >
140 mmHg or diastolic blood pressure > 90 mm
Hg), dyslipidemia {LDL (low density lipoprotein)
cholesterol 160 mg/dL, HDL (high-density lipo-
protein) cholesterol < 40 mg/dL, or triglyceride
200 mg/dL}, type 2 diabetes, coronary heart dis-
ease, stroke, thyroid disease, and depression. In-
formation was obtained by administering a self-
report questionnaire to patients and by clinical
examination and blood tests. Current smokers and
those who had undergone a commercial diet pro-
gram or received anti-obesity medication during
the previous three months were also excluded. As
in our previous study, obese subjects were
matched with healthy, premenopausal non-obese
women for clinical, metabolic, and lipid charac-
teristics. Initially, 42 obese patients were enrolled,
but six dropped out over the 12-week study
period, leaving a total of 36 subjects. All subjects
were given informed consent, and the study pro-
tocol was approved by the Institutional Review
Board of Ewha Womans University, Mokdong
Hospital.
Data collection
All examinations were performed during the
follicular phase of the menstrual cycle, within 10
days of the onset of menstruation. Subjects re-
ceived dietary and exercise consultations every
two weeks for three months, during which BP,
height, weight, and waist and hip circumferences
were measured.
Anthropometric measurements
Body weights were measured to an accuracy of
0.1 kg, with subjects wearing light clothing.
Height was measured to an accuracy of 0.1 cm.
The waist circumference was measured at the
mid-point between the upper iliac and lower
costal level at the end of normal expiration, to an
accuracy of 0.1 cm, and the hip circumference was
defined as the largest measurement around the
hip area. Body mass index (BMI) was calculated
as the weight in kilograms divided by the square
of the height in meters (kg/m
2).
Body fat measurements
Percent body fat (%) was measured using bio-
electrical impedance analysis while subjects were
in a fasting state (Inbody 2.0, Biospace Co., Seoul,
Korea), and body fat distribution was determined
by computed tomography (GE High Speed Ad-
vantage CT scanner, GE Co., Waukesha, USA).
Single slices of abdominal subcutaneous adipose
tissue and visceral adipose tissue (measured in
cm
2) were taken at the 4-5 level of the lumbar
spine, as described elsewhere.
9 The attenuation
interval was -40 to -140 Hounsfield units.
Blood tests
Plasma glucose, total cholesterol, HDL choles-
terol, LDL cholesterol, triglyceride, and non-
esterified fatty acid (NEFA) concentrations were
measured after overnight fasting for at least 12
hours. Plasma insulin was measured by radioim-
munoassay. Estradiol levels were measured by
microparticle enzyme immunoassay (Axsym,Reduction in Visceral Adiposity is Highly Related to Improvement in Vascular Endothelial Dysfunction among Obese Women
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Abbott, Abbott Park, Illinois, USA). Levels of
high-density C-reactive protein (hsCRP) were
measured by nephelometry using BNII (Dade
Behring, Liederbach, Germany) with a mini-
mum detection concentration of 0.0175 mg/dL.
Homeostasis Model Assessment (HOMA) scores
were calculated to evaluate insulin resistance.
10
Evaluation of vascular endothelial function
Pulse wave analysis using the provocative phar-
macological test was performed by administering
salbutamol or nitroglycerin (NTG) to determine
VED.
Pulse wave analysis
A pulse wave is composed of two waves, i.e.,
an aortic wave produced when the left ventricle
contracts and a reflected wave produced when the
aortic wave is reflected from peripheral vessels.
The velocity of the reflected waves is increased
when the arterial walls are stiff. Accordingly, in
cases with stiffened arteries, systolic pressure aug-
mentation occurs during the systolic phase. Based
on this principle, radial artery pressure was
measured using a high-fidelity micromanometer
(SphygmoCor, Medical ECONET Co., Sydney,
Australia). In practice, the artery is compressed
between a sensor and the underlying structures,
and, thus, the intra-arterial pressure is transmitted
through the arterial wall to the sensor. Data were
collected directly using a portable computer. After
20 sequential waveforms had been acquired, in-
tegral software was used to generate an averaged
peripheral waveform and a corresponding central
waveform. Further analysis was conducted to
determine AIx and the ascending aortic pressure,
as described previously.
7,11,12 AIx was defined as
the difference between the first (P1) and second
(P2) peaks of the central arterial waveform, ex-
pressed as a percentage of pulse pressure.
13,14 In
this study, repeated pulse wave analyses at
one-week intervals in ten non-obese volunteers
showed a coefficient of variance (CV) of 1.4 ± 2.3
% for AIx.
Measurements of aix after salbutamol or ntg admini-
stration
AIx was evaluated after administering nitrogly-
cerin or salbutamol, which induce endothelial-
independent vasodilation and endothelial-depen-
dent vasodilation, respectively. AIx was deter-
mined during the peak response which occurred
3 minutes after administering 0.6 mg of nitrogly-
cerin. The difference in AIx before and after this
administration was measured and is depicted as
AIx-NTG. Twenty-five minutes after admini-
stering nitroglycerin, 2.5 mg of nebulized salbuta-
mol (Ventolin nebules), which acts on vascular
endothelial cells through the L-arginine-NO path-
way, was administered by inhalation using a
mask. Thiry minutes later, the pulse wave an-
alysis was again carried out to measure AIx. The
difference between AIx before and after salbuta-
mol administration was then determined and is
depicted as AIx-Salb.
5,7,11 The dosage and
timing of the administration of these drugs were
based on pilot studies and previous experience.
Pilot studies confirmed that 15 minutes was
sufficient to allow NTG-induced hemodynamic
changes to return to baseline, but that a longer
period was required for salbutamol. Therefore,
NTG was always administered first, and followed
by salbutamol 25 minutes later.
Diet and exercise program
For effective weight control, a diet and exercise
program was utilized, and subjects were ed-
ucated regarding living habits. To maintain a low
calorie/low fat diet, subjects received 1,000 kcal
per day during the program. Initially, subjects ex-
ercised for half an hour a day, 3 times a week. The
length and frequency of exercise were then in-
creased every other week, reaching 40-60 minutes
a day and 4-5 times a week. Subject compliance
was evaluated at every visit by examining the
dietary diary and weight loss log. Subjects were
administered 20 mg of fluoxetine daily, as well as
a thermogenic agent (pseudoephedrine 60 mg,
theolan 100 mg) as a supplementary measure. To
avoid side-effects, drugs were administered for
the first 4 weeks only. Three months later, physi-
cal examinations, obesity measurements, and
pulse wave analysis were repeated.
Statistical analysisSi-Hoon Park and Kyung Won Shim
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All data are expressed as means±SD. Changes
in AIx-NTG, AIx-Salb and all other param-
eters versus weight reduction were analyzed
using a paired t-test. To identify parameters af-
fecting (AIx-Salb, a multiple linear regression
model was constructed using the step-wise
method, after adjusting for BMI with (AIx-Salb as
the dependent variable. hsCRP was log trans-
formed to achieve a normal distribution. The level
of significance was set at p < 0.05 (two-tailed).
Statistical calculations were performed using the
SAS system for Windows (version 8.0, SAS Inc.
Raleigh, NC, USA).
RESULTS
Anthropometric and clinico-metabolic responses
to weight reduction
After 12 weeks of the diet and exercise pro-
gram, all subjects were re-evaluated. The average
weight reduction was 7.96 ± 3.47 kg (11% of base-
line), with losses of 5.29±2.59 kg (13% of baseline)
in fat mass (p<0.001) and a marked reduction in
BMI and waist circumferences. The visceral and
subcutaneous fat areas were reduced by 21.88 ±
20.39 cm
2 and 49.01 ± 53.76 cm
2, respectively (p <
0.001). Diastolic pressure was slightly reduced,
without a significant change in systolic pressure.
The levels of total cholesterol, LDL cholesterol,
and triglycerides were all reduced after weight
reduction, but the serum HDL cholesterol level
did not show an increase following weight reduc-
tion. Fasting glucose, fasting insulin, HOMA
scores, and hsCRP levels were lower following
weight reduction, while estradiol levels increased
(Table 1).
Vascular reactivity and hemodynamic changes
by weight reduction. Baseline heart rate, mean
arterial pressure (MAP), and baseline AIx were
not significantly changed by weight reduction.




After weight reduction (N=36) p-value
Weight (kg) 74.32 ± 12.04 66.36 ± 10.04 <0.001
BMI (kg/m
2) 29.48 ± 4.39 26.29 ± 3.67 <0.001
Waist circumference (cm) 90.46 ± 1.72 83.47 ± 1.45 <0.001
Percent body fat (%) 38.54 ± 4.39 35.05 ± 4.23 <0.001
Abdominal adipose tissue area (cm
2)
Subcutaneous 331.05 ± 107.10 282.04 ± 81.66 <0.001
Visceral 97.17 ± 39.87 75.29 ± 32.27 <0.001
SBP (mmHg) 119.67 ± 9.89 122.53 ± 8.38 0.115
DBP (mmHg) 72.03 ± 6.21 70.94 ± 6.59 0.016
Cholesterol (mg/dL) 197.03 ± 25.61 176.69 ± 26.44 <0.001
LDL cholesterol (mg/dL) 95.00 ± 18.32 85.03 ± 15.32 <0.001
HDL cholesterol (mg/dL) 53.53 ± 9.25 54.67 ± 11.11 0.393
Triglyceride (mg/dL) 100.78 ± 35.70 85.00 ± 40.76 0.030
Fasting glucose (mg/dL) 96.58 ± 7.41 91.58 ± 7.41 0.007
Fasting insulin (μIU/mL) 12.55 ± 17.31 6.67 ± 5.22 0.002
HOMA score 3.13 ± 4.63 1.53 ± 1.24 0.030
NEFA (μEq/L) 487.03 ± 247.56 402.00 ± 207.91 0.076
hsCRP* (mg/dL) 0.25 ± 0.41 0.19 ± 0.36 <0.001
Estradiol (pg/mL) 64.17 ± 27.76 91.19 ± 41.72 0.002
*hsCRP was logarithmically transformed before analysis and is presented as median ± interquartile difference. Values are mean ± SD.
SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density ipoprotein; HDL, high-density lipoprotein; HOMA score,
homeostasis model assessment score; NEFA, non-esterified free fatty acid; hsCRP, high-sensitive C-reactive protein.Reduction in Visceral Adiposity is Highly Related to Improvement in Vascular Endothelial Dysfunction among Obese Women
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Changes in heart rate and MAP provoked by the
administration of NTG or salbutamol before
weight loss were similar to changes after weight
reduction (Table 2). Pulse wave analysis combined
with provocative pharmacological testing dem-
onstrated preserved endothelium-independent
vasodilation in healthy premenopausal obese
women ( AIx-NTG: 31.36 ± 9.80% before weight
reduction vs. 28.25 ± 11.21% after weight reduc-
tion, p > 0.05) and an improvement in endothelial-
dependent vasodilation following weight reduc-
tion ( AIx-Salb: 10.03 ± 6.49% before weight re-
duction vs. 19.33 ± 9.28% after reduction, p <
0.001) (Table 2).
Relationship between anthropometric and clinico-
metabolic parameters and weight reduction
Improvements in endothelial-dependent vas-
cular function following weight reduction (in-
crease in AIx-Salb by weight reduction) were
related to reductions in visceral adipose tissue
area (r=-0.62, p<0.001), percent body fat (r=-0.35,
p < 0.05), BMI (r=-0.33, p<0.05), fasting insulin (r=
-0.38, p<0.05), and HOMA scores (r=-0.375, p <
0.05). Moreover, step-wise multiple regression an-
alysis identified visceral adipose tissue area (β=
-0.57, p < 0.001) as the most significant indepen-
dent parameter accounting for improved endo-
thelial-dependent vascular function following
weight reduction (Table 3).
DISCUSSION
Obesity is characterized by VED, and the degree
of VED is predicted by body fat distribution,
independent of metabolic and other hemodynamic
parameters.
15,16 This association between obesity
and VED, an early feature of cardiovascular dis-
ease, is of great importance because it may pro-
vide clinicians with new preventive strategies
against atherosclerosis in obese patients. Recently,
a prospective study demonstrated VED improve-
ment following substantial weight reduction in
postmenopausal obese women with no additional
Table 3. Multiple Regression Analysis of Change in AIx-Salb in Obese Women
Obese women (N=36) β p-value







AIx-Salb, change in augmentation index by administering salbutamol; Visceral adipose tissue area, change of visceral adipose
tissue area; HOMA, change of homeostasis model assessment score.
Table 2. Pulse Wave Analysis Results Before and After Weight Reduction
Variables Before weight reduction (N=36) After weight reduction (N=36) p-value
Baseline AIx (%) 22.64 ± 11.25 22.92 ± 9.09 0.859
AIx NTG (%) 31.36 ± 9.80 28.25 ± 11.21 0.251
AIx Salb (%) 10.03 ± 6.49 19.33 ± 9.28 <0.001
Baseline HR (beat/min) 71.83 ± 7.95 70.31 ± 13.55 0.484
HR NTG (beat/min) 14.64 ± 11.15 6.25 ± 25.78 0.054
HR Salb (beat/min) 4.19 ± 5.98 0.81 ± 20.37 0.329
Baseline MAP (mmHg) 89.28 ± 1.14 86.14 ± 2.41 0.163
MAP NTG (mmHg) 3.56 ± 0.41 1.86 ± 2.27 0.574
MAP Salb (mmHg) 2.00 ± 0.52 0.36 ± 2.30 0.991
Values are mean ± SD.
AIx, Augmentation Index; AIx-NTG, change in augmentation index by administering nitroglycerin; AIx-Salb, change in augmen-
tation index by administering salbutamol; HR, Heart rate; HR-NTG, change in heart rate by administering nitroglycerin; HR-Salb,
change in heart rate by administering salbutamol; MAP, mean arterial pressure; MAP-NTG, change in mean arterial pressure by
administering nitroglycerin; MAP-Salb, change in mean arterial pressure by administering salbutamol.Si-Hoon Park and Kyung Won Shim
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risk factors.
4 However, the study tested VED by
determining hemodynamic and rheologic re-
sponses to L-arginine, a technique that may be
inadequate for screening or clinical applications.
A simple and noninvasive form of pulse wave
analysis to determine VED was recently intro-
duced.
5,6 In the present study, we used pulse
wave analysis, combined with provocative phar-
macological testing, to determine VED. To our
knowledge, this is the first report to prospectively
test the impact of weight reduction per se on VED
by pulse wave analysis. The main finding of this
study is that substantial weight reduction over a
12-week period can improve VED, and that
visceral fat reduction is most strongly related to
VED improvement in premenopausal obese
women.
Relationship between visceral adiposity and
VED
Adipose tissue acts as an endocrine organ and
appears to secrete metabolic pro-inflammatory
molecules. These cytokines are known to con-
tribute to vascular inflammation and to regulate
vascular endothelial function, an early indicator of
atherosclerosis development. Moreover, visceral
fat appears to produce these cytokines more ac-
tively than other adipose tissues. Visceral fat cells
show higher rates of catecholamine-induced
lipolysis and express higher numbers of β1- and
β2-adrenergic receptors and levels of glucocor-
ticoid receptor mRNA, thus explaining the impor-
tance of fat distribution.
17 Aging and estrogen
deficiency can play a role in changes in vascular
endothelium. After menopause, the possibility of
obesity-related complications is likely to increase.
Other cardiovascular risk factors, such as hyper-
tension, diabetes mellitus, hypercholesterolemia,
and smoking are also associated with VED. Thus,
we confined our study to premenopausal obese
women without additional cardiovascular risk
factors in order to reduce the effect of such factors
on VED.
18 In a previous study, we found that
provocative pharmacological testing using NTG
showed preserved endothelium-independent vaso-
dilation in premenopausal, healthy, obese women.
However, changes in AIx after the introduction of
salbutamol nebulas, which induces vasodilation
through vascular endothelial cells, was less
evident in the obese group than in the non-obese
group. The results of the present study suggest
that endothelial vasodilatory function is reduced
in premenopausal healthy obese women despite a
similar level of arterial stiffness, thus confirming
that visceral fat per se is highly associated with
VED.
Relationship between reduced visceral adiposity
and improved VED
Vascular endothelial function is affected by car-
diovascular risk factors, hormones, and medica-









24,25 hormone replacement therapy,
26,27 and
physical inactivity.
28 Weight reduction improves
many of the conditions frequently associated with
or co-occur with obesity. This raises the question
of whether the restoration of vascular endothelial
function by weight reduction in obese people is
due to visceral adiposity reduction, an improve-
ment in cardiovascular risk factors, or increased
physical activity. A recent study
4 demonstrated
that a reduction of visceral adipose tissue in obese
women is a more important factor than increased
physical activity or improvement of cardiovas-
cular risk factors in improving VED. The study
4
showed that a reduction in adipose tissue by lipo-
suction surgery improved VED and highlighted
the importance of visceral adiposity reduction in
and of itself in improving VED in obese women.
Pulse wave analysis for the evaluation of VED
Vascular endothelial cell function was measured
using pulse wave analysis. The results of pulse
wave analysis following the administration of
salbutamol or NTG has been shown to correlate
with the results of invasive methods based on
acetylcholine infusion.
5 The augmentation index
was used to assess VED in the present study.
Compared to established methods for assessing
vascular endothelial function, AIx combined with
a drug challenge is a non-invasive, simple, and
convenient method that is useful for the early
detection and assessment of VED.
5,29 Recently,Reduction in Visceral Adiposity is Highly Related to Improvement in Vascular Endothelial Dysfunction among Obese Women
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however, some questions have been raised about
the validity and clinical utility of pulse wave
analysis. Wide margins of error were found when
comparing centrally measured and peripherally
derived AIx.
30 AIx was also found to be depen-
dent on heart rate and blood pressure during IV
infusion of beta-adrenergic drugs, such as isopro-
terenol.
31 However, the inhalation of albuterol was
not accompanied by significant alterations in heart
rate and MAP.
5 We also confirmed in a previous
study that a substantial change in heart rate or
MAP was not induced by NTG or salbutamol. In
the present study, changes in AIx-Salb by
weight reduction were not related to a small
change in heart rate or diastolic or systolic pres-
sure (Table 3). Moreover, as the absolute value of
AIx might not be of importance in follow-up
studies,
32 we used AIx with provocative pharma-
cological testing in this study. Since all subjects
were premenopausal women free of cardiovas-
cular disease, it remains to be determined whether
our findings can be applied to men, children,
postmenopausal women, and cardiovascular
patients.
In conclusion, we have demonstrated that a
reduction in visceral adiposity is significantly re-
lated to improvements in VED, as determined by
radial artery pulse wave analysis, following
weight reduction. In this context, clinicians may
choose to focus on the reduction of visceral adi-
posity, as much as on the control of other risk fac-
tors, for the prevention of atherosclerosis in obese
women.
REFERENCES
1. Eckel RH, Krauss RM. American Heart Association call
to action: obesity as a major risk factor for coronary
heart disease. Circulation 1998;37:2099-100.
2. Terry RB, Page WF, Haskell WL. Waist-hip ratio, body
mass index and premature cardiovascular disease
mortality in US Army veterans during a twenty-three
year follow up study. Int J Obes Relat Metab Disord
1992;16:417-23.
3. Tracy RP. Inflammation in cardiovascular disease; cart,
horse, or both? Circulation 1998;97:2000-2.
4. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella
R, Cioffi M, et al. Reduction of inflammatory cytokine
concentrations and improvement of endothelial func-
tions in obese women after weight loss over one year.
Circulation 2002;105:804-9.
5. Wilkinson IB, Hall IR, MacCallum H, Mackenzie IS,
McEniery CM, van der Arend BJ, et al. Pulse-wave
analysis: clinical evaluation of a noninvasive, widely
applicable method for assessing endothelial function.
Arterioscler Thromb Vasc Biol 2002;22:147-52.
6. Hayward CS, Kraidly M, Webb CM, Collins P. Assess-
ment of endothelial function using peripheral wave-
form analysis. J Am Coll Cardiol 2002;40:521-8.
7. Chowienczyk PJ, Kelly RP, MacCallum H, Millasseau
SC, Andersson TL, Gosling RG, et al. Photoplethysmo-
graphic assessment of pulse wave reflection: blunted
response to endothelium-dependent beta 2-adrenergic
vasodilation in type II diabetes mellitus. J Am Coll
Cardiol 1999;34:2007-14.
8. Suh HS, Park YW, Kang JH, Lee SH, Lee HS, Shim KW.
Vascular endothelial dysfunction tested by blunted
response to endothelium-dependent vasodilation by
salbutamol and its related factors in uncomplicated
pre-menopausal obese women. Int J Obes Relat Metab
Disord 2005;29:217-22.
9. Shuman WP, Morris LL, Leonetti DL, Wahl PW, Moceri
VM, Moss AA, et al. Abdominal body fat distribution
detected by computed tomography in diabetic men.
Invest Radiol 1986;21:483-7.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA,
Treacher DF, Turner RC. Homeostasis model asses-
ment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentration in
man. Diabetologia 1985;28:412-9.
11. Dawes M, Chowienczyk PJ, Ritter JM. Effects of inhi-
bition of the L-arginine/NO pathway on beta-adre-
nergic mediated vasodilation in human forearm vas-
culature. Circulation 1997;95:2293-7.
12. Kelly R, Hayward C, Avolio A, O'Rourke M. Nonin-
vasive determination of age-related changes in the
human arterial pulse. Circulation 1989;80:1652-9.
13. Seger P, Qasem A, DeBacker T, Carlier S, Verdonck P,
Avolio A. Peripheral 'oscillatory' compliance is asso-
ciated with aortic augmentation index. Hypertension
2001;37:1434-9.
14. Mackenzie IS, Wilkinson IB, Cockcroft JR. Assessment
of arterial stiffness in clinical practice. Q J Med 2002;
95:67-74.
15. Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G,
Armellini F, et al. Body fat distribution predicts the
degree of endothelial dysfunction in uncomplicated
obesity. Int J Obes Relat Metab Disord 1999;23:936-42.
16. Hashimoto M, Akishita M, Eto M, Kozaki K, Ako J. The
impairment of flow-mediated vasodilatation in obese
men with visceral fat accumulation. Int J Obes Relat
Metab Disord 1998;22:477-84.
17. Montague CT, O'Rahilly S. The perils of portliness:
causes and consequences of visceral adiposity. Diabetes
2000;49:883-8.
18. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA,
Holmes DR Jr, Lerman A. Long-term follow-up of pa-
tients with mild coronary artery disease and endo-Si-Hoon Park and Kyung Won Shim
Yonsei Med J Vol. 46, No. 4, 2005
thelial dysfunction. Circulation 2000;101:948-54.
19. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ,
Newell-Morris L, Kahn SE, et al. Visceral adiposity is
an independent predictor of incident hypertension in
Japanese Americans. Ann Intern Med 2004;140:992-
1000.
20. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM.
Impaired endothelium dependent vasodilation of fore-
arm resistance vessels in hypercholesterolaemia. Lancet
1992;340:1430-2.
21. Celermajer DS, Sorensen KE, Spiegelhalter DJ,
Georgakopoulos D, Robinson J, Deanfield JE. Aging is
associated with endothelial dysfunction in healthy men
years before the age-related decline in women. J Am
Coll Cardiol 1994;24:471-6.
22. Lieberman EH, Gerhard MD, Uehata A, Walsh BW,
Selwyn AP, Ganz P, et al. Estrogen improves endo-
thelium-dependent, flow mediated vasodilation in post-
menopausal women. Ann Intern Med 1994;121:936-41.
23. Clarkson P, Celermajer DS, Donald AE, Sampson M,
Sorensen KE, Adams M, et al. Impaired vascular
reactivity in insulin-dependent diabetes mellitus is
related to disease duration and low density lipoprotein
cholesterol levels. J Am Coll Cardiol 1996;28:573-9.
24. Vogel RA, Corretti MC, Plotnick GD. Changes in flow-
mediated brachial artery vasoactivity with lowering of
desirable cholesterol levels in healthy middle-aged
men. Am J Cardiol 1996;77:37-40.
25. O'Driscoll G, Green D, Taylor RR. Simvastatin, an
HMG-coenzyme A reductase inhibitor, improves endo-
thelial function within 1 month. Circulation 1997;95:
1126-31.
26. Gerhard M, Walsh BW, Tawakol A. Haley EA, Creager
SJ, Seely EW, et al. Estradiol therapy combined with
progesterone and endothelium-dependent vasodilation
in postmenopausal women. Circulation 1998;98:1158-63.
27. Sorensen KE, Dorup I, Hermann AP, Mosekilde L.
Combined hormone replacement therapy does not pro-
tect women against the age-related decline in endothe-
lium-dependent vasomotor function. Circulation 1998;
97:1234-8.
28. Gill JM, Al-Mamari A, Ferrell WR, Cleland SJ, Packard
CJ, Sattar N, et al. Effects of prior moderate exercise on
postprandial metabolism and vascular function in lean
and centrally obese men. J Am Coll Cardiol 2004;21:
2375-82.
29. Anderson TJ, Uehata A, Gerhard MD, Meredith IT.
Close relation of endothelial function in the human
coronary and peripheral circulations. J Am Coll Cardiol
1995;26:1235-41.
30. Hope SA, Tay DB, Meredith IT, Cameron JD. Use of
arterial transfer functions for the derivation of arterial
wave form characteristics. J Hypertens 2003;21:1299-
305.
31. Lemogoum D, Flores G, Van den Abeele W, Ciarka A,
Leeman M, Degaute JP. Validity of pulse pressure and
augmentation index as surrogate measures of arterial
stiffness during beta-adrenergic stimulation. J Hyper-
tens 2004;22:511-7.
32. Williams B. Pulse wave analysis and hypertension: ev-
angelism versus skepticism. J Hypertens 2004;22:447-9.